Wedbush analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics (GBT) today and set a price target of $103. The company’s shares closed on Friday at $48.79.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -12.4% and a 28.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $90, which is an 84.5% upside from current levels. In a report issued on August 7, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $64.94 and a one-year low of $30.15. Currently, Global Blood Therapeutics has an average volume of 932.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
